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A bs tr ac t
Background
Fast and accurate staging is essential for choosing treatment for non–small-cell 
lung cancer (NSCLC). The purpose of this randomized study was to evaluate the 
clinical effect of combined positron-emission tomography and computed tomography 
(PET–CT) on preoperative staging of NSCLC.
Methods
We randomly assigned patients who were referred for preoperative staging of NSCLC 
to either conventional staging plus PET–CT or conventional staging alone. Patients 
were followed until death or for at least 12 months. The primary end point was the 
number of futile thoracotomies, defined as any one of the following: a thoracotomy 
with the finding of pathologically confirmed mediastinal lymph-node involvement 
(stage IIIA [N2]), stage IIIB or stage IV disease, or a benign lung lesion; an explora-
tory thoracotomy; or a thoracotomy in a patient who had recurrent disease or death 
from any cause within 1 year after randomization.
Results
From January 2002 through February 2007, we randomly assigned 98 patients to the 
PET–CT group and 91 to the conventional-staging group. Mediastinoscopy was per-
formed in 94% of the patients. After PET–CT, 38 patients were classified as having 
inoperable NSCLC, and after conventional staging, 18 patients were classified thus. 
Sixty patients in the PET–CT group and 73 in the conventional-staging group under-
went thoracotomy (P = 0.004). Among these thoracotomies, 21 in the PET–CT group 
and 38 in the conventional-staging group were futile (P = 0.05). The number of jus-
tified thoracotomies and survival were similar in the two groups.
Conclusions
The use of PET–CT for preoperative staging of NSCLC reduced both the total num-
ber of thoracotomies and the number of futile thoracotomies but did not affect 
overall mortality. (ClinicalTrials.gov number, NCT00867412.)
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Staging of non–small-cell lung can-cer (NSCLC) was one of the first approved indications for the use of positron-emis-
sion tomography (PET).1,2 Since 2001, combined 
PET and computed tomography (PET–CT) has rap-
idly replaced stand-alone PET.3,4 The diagnostic 
capability of PET–CT in the preoperative staging 
of NSCLC is superior to that of CT alone and PET 
alone.5 The advantage is based mainly on a more 
accurate assignment of tumor stage (T stage) and 
to a lesser extent on defining the lymph-node 
stage (N stage).5-7 Whether the improved diagnos-
tic accuracy improves management of the disease 
is unknown.
Two randomized trials have assessed the clini-
cal effect of stand-alone PET. In a trial by van 
Tinteren et al.,8 the addition of stand-alone PET 
to conventional staging of NSCLC reduced the 
number of futile thoracotomies by 50%. A second 
randomized trial, however, did not show that add-
ing PET reduced the number of thoracotomies.9
Identifying the stage of lung cancer helps de-
termine the appropriate treatment and is essen-
tial for prognosis.10,11 Incorrect staging of NSCLC 
can result in resections of benign nodules and 
early local or distant relapse after surgery with 
curative intent.8,12 We report on a randomized 
trial to assess the clinical influence of preopera-
tive staging with PET–CT.
Me thods
Patients
We recruited patients from three departments of 
pulmonology in the area of Copenhagen. Patients 
were eligible if they were 18 to 80 years of age, 
had newly diagnosed or highly suspected NSCLC, 
and were considered to have operable disease 
after conventional-staging procedures13 (i.e., med-
ical history, physical examination, blood test, 
contrast-enhanced CT scan of the chest and up-
per abdomen, and bronchoscopy). Exclusion cri-
teria were type 1 diabetes, another malignant 
condition, confirmed distant metastases, known 
claustrophobia, and an estimated forced expira-
tory volume in 1 second of less than 30% after 
surgery. After conventional staging, eligible pa-
tients were randomly assigned in a 1:1 ratio to 
PET–CT and conventional staging, followed by fur-
ther invasive diagnostic procedures such as medi-
astinoscopy and endoscopic or endobronchial 
ultrasonography (the PET–CT group), or to con-
ventional staging and invasive diagnostic proce-
dures alone (the conventional-staging group). In 
both groups, mediastinoscopy was mandatory. 
Randomization was performed centrally with the 
use of a permuted-block design, stratified accord-
ing to sex and recruiting center.
Study design
The study was initiated by the investigators, and 
the authors planned the study, gathered and ana-
lyzed data, wrote the manuscript, and made the 
decision to publish the findings. No financial 
support was received from companies that make 
PET–CT scanners. The study was approved by the 
ethics committee of each participating hospital 
and was conducted according to the Declarations 
of Helsinki and Tokyo. Written informed consent 
was obtained from all patients. Data were collect-
ed in a central database, managed by the Clinical 
Research Unit at the Department of Oncology, 
Rigshospitalet, Copenhagen.
PET–CT imaging
All PET–CT scans were obtained in the Depart-
ment of Clinical Physiology, Nuclear Medicine, 
and PET, Rigshospitalet. After a 6-hour fast, 400 
MBq of 18F-fluorodeoxyglucose (18F-FDG) was 
given intravenously, and after a 1-hour rest, the 
patient was scanned from the head to the upper 
thigh with the use of an integrated PET–CT sys-
tem (GE Discovery LS, GE Healthcare). A diagnos-
tic CT scan, obtained with the use of a standard 
protocol (80 to 100 mA, 120 kV, a tube-rotation 
time of 0.5 second per rotation, a pitch of 6, and 
a slice thickness of 5 mm, with 70 ml of intrave-
nous contrast medium containing 300 mg of 
iodine per milliliter [Ultravist, Bayer Schering], 
administered at a rate of 2.5 ml per second), pre-
ceded the PET scan (a 5-minute emission scan 
per table position and 25 minutes total). The PET 
scan was reconstructed by filtered back-projection 
and ordered-subset expectation-maximization 
(OS-EM), with data from the CT scan used for 
attenuation correction.
An experienced radiologist and a nuclear med-
icine specialist evaluated the PET–CT images side 
by side, and a consensus was reached on the find-
ings. A lesion with increased uptake of 18F-FDG 
in three planes as compared with background on 
a PET scan was classified as malignant. If the 
image could not be interpreted with confidence, 
the standardized uptake value (SUV), defined as 
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the activity per milliliter within the region of 
interest divided by the injected dose in megabec-
querels per gram of body weight, was calculated, 
and lesions with an SUV above 2.5 were deemed 
malignant. The tumor–node–metastasis (TNM) 
stage was assigned according to the revised clas-
sification of Mountain.14
Treatment and follow-up
Before a decision to operate was made, a consen-
sus on the TNM stage was reached by a pulmo-
nologist and a thoracic surgeon on the basis of 
all available information (clinical data, initial CT 
scanning, PET–CT imaging, bronchoscopy, medi-
astinoscopy, and if available, endoscopic ultra-
sonography with fine-needle aspiration or endo-
bronchial ultrasonography). Mediastinoscopy and 
endoscopic or endobronchial ultrasonography 
served as the standard for preoperative assess-
ment of mediastinal lymph nodes. All patients 
with stage I to stage IIB NSCLC were offered sur-
gery. Patients with involvement of mediastinal 
Table 1. Characteristics of the Patients at Baseline.*
Characteristic
PET–CT 
(N = 98)
Conventional Staging 
(N = 91) P Value
Patients
Age (yr) 0.22
Mean 63 64 
Range 42–80 38–80
Male sex (no. of patients) 53 49
0.97
Female sex (no. of patients) 45 42
ECOG performance status (no. of patients)† 0.89
0–1 93 86
2 1  1
Not available 4  4
Lactate dehydrogenase (U/liter) 0.91
Mean 290 288
Range 107–618 119–688
Tumor
Size on CT (mm) 0.35
Mean 46.5 43.6
Range 10.0–110.0 15.0–130.0
Localization in lung on CT (no. of foci) 0.72
Central 15 12
Intermediate 13 10
Peripheral 22 20
Not available 42 49
Prerandomization assessments
TNM stage based on CT of thorax and abdomen (no. of patients) 0.77
IA 13  9
IB 17 13
IIA 0  0
IIB 5  7
IIIA 26 28
IIIB 32 32
IV‡ 5  2
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lymph nodes or distant metastases (stage IIIA 
[N2] to stage IV) were considered to have inoper-
able disease and were offered chemotherapy with 
or without radiotherapy. Positive findings on 
PET–CT were further evaluated by biopsy or other 
imaging techniques (ultrasonography, radiogra-
phy, or magnetic resonance imaging) at the dis-
cretion of the referring clinician. Follow-up data 
were retrieved from medical records and the local 
registry of patients.
Statistical analysis
The primary end point of the study was the fre-
quency of futile thoracotomies. The criteria for 
classifying a thoracotomy as futile included any 
one of the following findings or results: a benign 
lung lesion, pathologically proven mediastinal 
lymph-node involvement (stage IIIA [N2]), stage 
IIIB or IV disease, inoperable T3 or T4 disease, or 
recurrent disease or death from any cause within 
1 year after randomization.8
To observe a difference of 15% in the number 
of futile thoracotomies between the PET–CT 
group and the conventional-staging group, with 
two-sided type I and type II error rates of 5% 
and 10%, respectively, an estimated 215 consecu-
tive, unselected patients would have to be ran-
domly assigned to each group. An interim analy-
sis was planned after the inclusion of 220 patients. 
However, the study was closed after the inclusion 
of only 189 patients because of slow accrual. 
Until then, no data were analyzed.
The total number of thoracotomies and the 
number of futile thoracotomies in each group 
were compared by means of a chi-square test 
with a two-sided significance level of 0.05. When 
Table 1. (Continued.)
Characteristic
PET–CT 
(N = 98)
Conventional Staging 
(N = 91) P Value
Ultrasonography of abdomen (no. of patients) 7  6
Cytology on pleural effusion (no. of patients) 1  2 0.61
MRI of the brain (no. of patients) 1  0
Mediastinoscopy (no. of patients)
Total 89 88
Positive yield§ 9 12 0.35
Endoscopic ultrasonography (no. of patients)
Total 42 30 0.18
Fine­needle aspiration 36 24
Positive yield§ 16  7 0.32
Histologic features at operation (no. of patients) 0.28
Squamous­cell carcinoma 22 22
Adenocarcinoma 30 29
Large­cell carcinoma 4 12
Bronchoalveolar carcinoma 0  1
NSCLC with no further specification 5  4
Other¶ 2  2
Benign lung lesion 0  3
* ECOG denotes Eastern Cooperative Oncology Group, MRI magnetic resonance imaging, NSCLC non–small­cell lung can­
cer, PET–CT combination positron­emission tomography and computed tomography, and TNM tumor–node–metastasis.
† In this study, ECOG performance scores ranged from 0 to 2, with higher scores indicating greater impairment.
‡ In the PET–CT group, three patients had solitary metastasis in the ipsilateral lung but the other lobe, and two patients 
had unilateral adrenal metastasis. In the conventional­staging group, two patients had solitary metastasis in the ipsilat­
eral lung but the other lobe.
§ A positive yield was defined as stage N2 to N3 disease.
¶ In the PET–CT group, one patient had pleomorphic carcinoma, and one had carcinoid tumors. In the conventional­
staging group, one patient had adeno squamous carcinoma, and one had carcinoid tumors.
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the expected number in any cell was less than 
five, a Fisher’s exact test for two-by-two tables and 
a Fisher–Freeman–Halton test for two-by-k tables 
for binary comparison were used. Clinical charac-
teristics of patients at randomization were com-
pared with the use of an independent t-test for 
continuous variables and a chi-square test or 
Fisher’s exact test for categorical variables. All 
reported P values are two-sided and have not been 
adjusted for multiple comparisons. Confidence 
intervals for sensitivity and specificity were calcu-
lated with the use of the Wilson score method. 
Survival data were analyzed with the use of a 
log-rank test. Statistical analysis was performed 
with the use of SPSS software, version 16, and 
StatXact software, version 8.
R esult s
Baseline characteristics
From January 2002 through February 2007, a total 
of 189 patients were enrolled and randomly as-
signed to either the PET–CT group (98 patients) 
or the conventional-staging group (91 patients). 
Eleven patients in the PET–CT group did not un-
dergo PET–CT because of an unacceptably long 
waiting time for a scan or technical problems with 
the PET–CT equipment. One patient underwent 
PET–CT but declined all further staging proce-
dures and surgery. Mediastinoscopy was performed 
in 89 patients in the PET–CT group (91%) and 88 
in the conventional-staging group (97%) (P = 0.33). 
Endoscopic ultrasonography was performed in 
42 patients in the PET–CT group (43%) and 30 in 
the conventional-staging group (33%) (P = 0.18). 
Table 1 shows the clinical characteristics of the 
patients in the two groups.
Number of thoracotomies
After staging, 60 patients in the PET–CT group 
(61%) and 73 in the conventional-staging group 
(80%) were considered to have operable disease 
and underwent thoracotomy (P = 0.004) (Table 2). 
After the exclusion of the 14 patients in the PET–CT 
group who did not undergo PET–CT and the 1 pa-
tient who underwent PET–CT but declined all fur-
ther procedures, 52 of 83 patients in the PET–CT 
group (63%) underwent surgery, as did 73 of 91 in 
the conventional-staging group (80%) (P = 0.01).
In the PET–CT group, 38 patients were not 
offered surgery after final staging (Table 2). Of 
these 38 patients, 1 declined to undergo surgery, 
1 had unconfirmed stage IV disease, and 13 
(34%) were categorized as having inoperable 
NSCLC on the basis of PET–CT only. PET–CT 
scans showed previously unrecognized distant 
metastases in 9 of the 13 patients and unknown 
mediastinal metastases in 4 patients. The un-
known mediastinal metastases were confirmed 
by endoscopic ultrasonography (three patients) or 
endobronchial ultrasonography (one patient). Sev-
en patients in the PET–CT group had NSCLC that 
was categorized as inoperable on the basis of 
endoscopic ultrasonography with fine-needle as-
piration alone — according to TNM staging, two 
patients had N2 disease, three had N3 disease, 
and two had inoperable T4 disease. Sixteen pa-
tients had NSCLC that was categorized as inop-
erable on the basis of mediastinoscopy; in 10 of 
these patients, NSCLC was also categorized as 
inoperable on the basis of the PET–CT scan. Three 
of the 16 patients did not undergo PET–CT.
In the conventional-staging group, 18 patients 
were not offered surgery after final staging. No 
patient was found to have stage IV disease, but 
Table 2. Operability.*
Characteristic
PET–CT 
(N = 98)
Conventional 
Staging 
(N = 91)
Total 
(N = 189)
number (percent)
Operable
Yes† 60 (61) 73 (80) 133 (70)
No 38 (39) 18 (20) 56 (30)
Reason for nonoperability
Stage IV 11 (29) 0 11 (20)
Stage IIIB 12 (31) 6 (33) 18 (32)
Stage IIIA (N2) 14 (37) 12 (67) 26 (46)
Other‡ 1 (3) 0 1 (2)
Total 38 (100) 18 (100) 56 (100)
Reason for staging up
PET–CT 13 (34) 0 13 (23)
Endoscopic ultrasonography 7 (19) 7 (39) 14 (25)
CT plus mediastinoscopy 16 (42) 11 (61) 27 (48)
Other§ 2 (5) 0 2 (4)
* PET–CT denotes combination positron­emission tomography and computed 
tomography.
† P = 0.004 for the comparison between the two groups.
‡ One patient had stage IA non–small­cell lung cancer (NSCLC) at consensus 
on tumor–node–metastasis staging but declined to undergo surgery.
§ One patient had stage IA NSCLC but declined surgery, and one patient had 
stage IV NSCLC according to CT and PET–CT scans and declined further staging.
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6 patients had stage IIIB disease and 12 had 
stage IIIA (N2) disease. Endoscopic ultrasono-
graphic images showed unknown mediastinal 
metastases in 7 of these 18 patients. The remain-
ing 11 patients with inoperable NSCLC were cat-
egorized as such on the basis of mediastinoscopy.
Futile thoracotomies
Of the 60 patients in the PET–CT group who un-
derwent thoracotomy, the procedure was futile in 
21 patients (35%). In the conventional-staging 
group, 38 of 73 patients (52%) underwent a futile 
thoracotomy (P = 0.05) (Table 3). After the exclu-
sion of the 14 patients in the PET–CT group who 
did not undergo PET–CT and the 1 patient who 
underwent PET–CT but declined further proce-
dures, 13 of 52 patients in the PET–CT group 
(25%) underwent a futile thoracotomy, as com-
pared with 38 of 73 patients in the conventional-
staging group (52%) (P = 0.002). Altogether, a total 
of 21 of 98 patients in the PET–CT group (21%) 
and 38 of 91 in the conventional-staging group 
(42%) underwent a futile thoracotomy. In other 
words, for every five PET–CT scans, one futile 
thoracotomy was avoided.
A total of 39 patients in the PET–CT group 
(40%) and 35 in the conventional-staging group 
(38%) underwent surgery that was considered 
justifiable (nonfutile). Futile thoracotomies were 
performed in both groups, regardless of the clini-
cal stage at presentation (Table 4).
Diagnostic accuracy
The diagnostic accuracy and sensitivity of the 
staging regimen in the two groups in terms of 
predicting operability can be calculated, assum-
ing that none of the patients who were catego-
rized as having inoperable disease after staging 
should have undergone surgery (specificity, 100%). 
For the PET–CT group, the diagnostic accuracy 
and sensitivity were 79% (95% confidence inter-
val [CI], 69 to 86) and 64% (95% CI, 52 to 75), 
respectively. For the conventional-staging group, 
the accuracy and sensitivity were 60% (95% CI, 
50 to 70) and 32% (95% CI, 21 to 45), respectively.
Follow-up
All patients were followed until death or for at 
least 12 months after inclusion in the trial. The 
mean follow-up time in both groups was 27 
months. Chemotherapy, radiotherapy, or both 
were given in 61% of the patients in the PET–CT 
group and in 57% in the conventional-staging 
group (P = 0.05). There were no significant differ-
ences in survival between the two groups; medi-
an survival was 31 months in the PET–CT group 
and 49 months in the conventional-staging group 
(P = 0.29). At follow-up, 56% of all patients had 
died (61% in the PET–CT group and 51% in the 
conventional-staging group, P = 0.15). In most pa-
tients, death was caused by lung cancer; however, 
in six patients, death was caused by other factors. 
In the conventional-staging group, one patient 
with no known brain metastasis died from status 
epilepticus, and in the PET–CT group, five patients 
died from causes not directly related to lung can-
cer (stroke, esophageal cancer, exacerbation of 
chronic obstructive pulmonary disease, and acute 
myocardial infarction each caused one death, and 
one patient died of an unknown cause 4.5 years 
after successful surgery). One death in each group 
was attributable to complications after primary 
surgery.
Of the 21 patients in the PET–CT group who 
underwent a futile thoracotomy, 4 had a relapse 
or died from lung cancer within 1 year after in-
clusion in the trial (Table 3). Of the 38 patients 
in the conventional-staging group who underwent 
a futile thoracotomy, 13 had a relapse and 4 died 
of lung cancer within 1 year after inclusion.
Table 3. Distribution of Futile Thoracotomies.*
Characteristic PET–CT
Conventional 
Staging Total
number (percent)
Futile thoracotomy
No 39 (65) 35 (48) 74 (56)
Yes† 21 (35) 38 (52) 59 (44)
Total 60 (100) 73 (100) 133 (100)
Reason that thoracotomy was  
considered futile 
Exploratory thoracotomy 5 (24) 4 (11) 9 (15)
Benign lung lesion 0 3 (8) 3 (5)
Stage IV disease 3 (14) 0 3 (5)
Stage IIIB disease 4 (19) 8 (21) 12 (20)
Stage IIIA (N2) disease 5 (24) 6 (16) 11 (19)
Recurrence within 12 mo 3 (14) 13 (34) 16 (27)
Death within 12 mo 1 (5) 4 (11) 5 (8)
Total 21 (100) 38 (100) 59 (100)
* PET–CT denotes combination positron­emission tomography and computed 
tomography. Percentages may not total 100 because of rounding.
† P = 0.05 for the comparison between the two groups.
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During the follow-up period, 21 of 60 pa-
tients in the PET–CT group who underwent 
surgery and 26 of 73 in the conventional-staging 
group had a relapse (P = 0.94). In the PET–CT 
group, 62% of patients had a local or regional 
relapse and 38% a distant relapse. In the conven-
tional-staging group, 35% had a local or re-
gional relapse, whereas 58% had a relapse at 
distant sites (P = 0.007); localization of the re-
lapse was imprecise for the remaining 7%.
Discussion
This randomized trial of combined PET–CT for 
the staging of lung cancer was closed premature-
ly because of slow accrual, but the findings con-
firm that PET–CT improves the preoperative stag-
ing of NSCLC, as Lardinois and colleagues also 
found.5 Furthermore, PET–CT has a potential clin-
ical effect in that it reduces the number of futile 
thoracotomies and the total number of thoraco-
tomies.
Our findings are similar to the results of the 
2002 trial by van Tinteren et al. involving 188 pa-
tients with NSCLC,8 which showed that staging 
with stand-alone PET resulted in a relative reduc-
tion in the risk of futile thoracotomy of 51% and 
an absolute risk reduction of 20 percentage points. 
Despite a different distribution of clinical stage 
in the two studies (70% of the patients in the 
trial by van Tinteren et al. were classified as hav-
ing TNM stage I to stage II disease at presenta-
tion, whereas only 34% of our patients presented 
with localized disease), the results were similar.
The definition of futile thoracotomy is con-
troversial. Thoracotomy was considered futile if 
disease recurred or the patient died within 12 
months after surgery (Table 3), which was the 
case in 20% of the patients in the PET–CT group 
and 45% in the conventional-staging group. Ex-
cluding these patients, the percentage of futile 
thoracotomies was virtually the same in the two 
groups (28% and 29% of all thoracotomies, re-
spectively; P = 1.00). However, if our definition of 
futile thoracotomy is accepted as a valid end 
point, the significantly higher number of early 
deaths and relapses in the conventional-staging 
group than in the PET–CT group was not due to 
chance or more successful surgery in the PET–
CT group but instead reflects a better selection 
of patients for surgery in the PET–CT group.
An Australian multicenter study of 184 pa-
tients, 92% of whom had stage I NSCLC, showed 
no significant difference in the total number of 
thoracotomies between the group that underwent 
staging with stand-alone PET and the group that 
underwent staging without stand-alone PET.9 
This study, however, did not use confirmatory 
invasive procedures (only 10 patients underwent 
mediastinoscopy).15
One of the strengths of the present study is 
the use of mediastinoscopy in most patients 
(94%), which revealed positive lymph nodes in 
11% of the patients. Five of 21 patients in the 
PET–CT group (24%) and 6 of 38 patients in the 
conventional-staging group (16%) underwent 
thoracotomy that was futile because of inciden-
tal N2 disease (i.e., N2 disease detectable only by 
pathological examination of the surgical speci-
men). However, the effect of incidental N2 dis-
ease on the prognosis can be disputed, and it 
could be argued that these thoracotomies were 
not futile.16 Classifying the thoracotomies as 
justified in these 11 patients results in a fre-
quency of futile thoracotomies of 27% (16 of 60) 
in the PET–CT group and 44% (32 of 73) in the 
conventional-staging group, which is still a sig-
nificant difference (P = 0.04).
In conclusion, we found that adding a PET–
CT examination to the diagnostic regimen for 
patients with NSCLC improves sensitivity in pre-
operative staging. The addition of a PET–CT ex-
amination reduces the frequency of futile thora-
cotomies and the total number of thoracotomies, 
with no effect (negative or positive) on overall 
survival.
Table 4. Futile Thoracotomies According to Clinical Stage at Presentation.*
TNM Stage PET–CT† Conventional Staging‡
No Futile 
Thoracotomy
Futile 
Thoracotomy
No Futile 
Thoracotomy
Futile 
Thoracotomy
number (percent)
IA–IIB 20 (51) 10 (48) 13 (37) 14 (37)
IIIA 8 (21) 5 (24) 11 (31) 9 (24)
IIIB–IV 11 (28) 6 (29) 11 (31) 15 (39)
Total 39 (100) 21 (100) 35 (100) 38 (100)
* PET–CT denotes combination positron­emission tomography and computed 
tomography, and TNM tumor–node–metastasis. Percentages may not total 
100 because of rounding.
† P = 0.95 for the comparison between the performance of and the nonperfor­
mance of thoracotomy.
‡ P = 0.70 for the comparison between the performance of and the nonperfor­
mance of thoracotomy.
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